Brijesh M. Shah

Dr. Brijesh M. Shah

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

27 January 2014 in Drug Delivery
Verified
Journal Article
Closed access
BSBrijesh M. Shah
Brijesh M. Shah
MMmanju misra
manju misra
CSChamanlal J. Shishoo
Chamanlal J. Shishoo
HPHarish Padh
Harish Padh
Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to irreversible loss of neurons, cognition and formation of abnormal protein aggregates. Rivastigmine, a reversible cholinesterase inhibitor used for the treatment of AD, undergoes extensive first-pass metabolism, thus limiting its absolute bioavailability to only 36% after 3-mg dose. Due to extreme aqueous solubility, rivastigmine shows poor penetration and lesser concentration in the brain thus requiring frequent oral dosing. This investigation was aimed to formulate microemulsion (ME) and mucoadhesive microemulsions (MMEs) of rivastigmine for nose to brain delivery and to compare percentage drug diffused for both systems using in-vitro and ex-vivo study. Rivastigmine-loaded ME and MMEs were prepared by titration method and characterized for drug content, globule size distribution, zeta potential, pH, viscosity and nasal ciliotoxicity study. Rivastigmine-loaded ME system containing 8% w/w Capmul MCM EP, 44% w/w Labrasol:Transcutol-P (1:1) and 48% w/w distilled water was formulated, whereas 0.3% w/w chitosan (CH) and cetyl trimethyl ammonium bromide (as mucoadhesive agents) were used to formulate MMEs, respectively. ME and MMEs formulations were transparent with drug content, globule size and zeta potential in the range of 98.59% to 99.43%, 53.8 nm to 55.4 nm and -2.73 mV to 6.52 mV, respectively. MME containing 0.3% w/w CH followed Higuchi model (r(2) = 0.9773) and showed highest diffusion coefficient. It was free from nasal ciliotoxicity and stable for three months. However, the potential of developed CH-based MME for nose to brain delivery of rivastigmine can only be established after in-vivo and biodistribution study.



1 June 2016 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
BSBrijesh M. Shah
Brijesh M. Shah
Dignesh KhuntDignesh Khunt
Dignesh Khunt
HBHimanshu Bhatt
Himanshu Bhatt
MMmanju misra
manju misra
HPHarish Padh
Harish Padh

2 January 2018 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
BSBrijesh M. Shah
Brijesh M. Shah
Dignesh KhuntDignesh Khunt
Dignesh Khunt
MMManju Misra
Manju Misra
HPHarish Padh
Harish Padh